Research and Clinical Trials

COG ACNS0332: Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Brief Description  
This trial is studying different chemotherapy and radiation therapy regimens to compare how well they work in treating young patients with newly diagnosed, previously untreated, high-risk medulloblastoma or supratentorial primitive neuroectodermal tumor.
Who may be Eligible  

  • Histologically confirmed diagnosis of medulloblastoma or supratentorial primitive neuroectodermal tumor (PNET)
    • Newly diagnosed disease
    • Previously untreated disease
  • Meets 1 of the following criteria:
    • M0 medulloblastoma with > 1.5 cm² residual tumor
    • M+ medulloblastoma
    • M0 or M+ supratentorial PNET
    • Diffusely anaplastic medulloblastoma with any M-stage or residual tumor
  • Must have undergone stereotactic biopsy or attempted neurosurgical resection of the tumor within the past 31 days
  • No M4 disease

  • Age 3 to 21 years
  • Not pregnant or nursing
  • No prior chemotherapy or radiotherapy
  • No other concurrent experimental therapy
  • No concurrent isotretinoin for acne treatment
  • No concurrent corticosteroids as an antiemetic during chemotherapy
Pediatric Cancer
IRB Number  
Principal Investigator  
Kaplan, Joel

For More Information, Contact  Lynnae  , Schwandt
Phone:  (704) 355-1188  Fax:  (704) 446-1989  
Address:1025 Morehead Medical Drive Suite 600 Charlotte, NC 28204